莫沙必利联合质子泵抑制剂治疗胃食管反流病的效果及药物安全性分析

Analysis of Mosapride combined with proton pump inhibitor effect in the treatment of gastroesophageal reflux disease and drug safety

目的探讨莫沙必利联合质子泵抑制剂治疗胃食管反流病患者的效果及安全性。方法选取2015年10月至2017年2月于茂名市人民医院门诊行胃镜检查确诊为胃食管反流病的患者90例为研究对象,随机分为3组,每组30例,3组患者分别给予雷贝拉唑肠溶胶囊、枸橼酸莫沙必利胶囊、雷贝拉唑钠肠溶胶囊联合莫沙必利胶囊治疗,连续治疗8周后,观察3组患者的治疗效果及治疗过程中药物不良反应发生情况。结果联合治疗组的显效治疗率(76.7%)及总有效治疗率(90.0%)均明显优于雷贝拉唑治疗组及莫沙必利治疗组,差异均有统计学意义(均P<0.05);3组患者药物不良反应发生率差异无统计学意义(P>0.05)。结论莫沙必利联合质子泵抑制剂治疗胃食管反流病,可以明显提高临床治疗效果,且安全性较高。

Objective To investigate the analysis of Mosapride combined with proton pump inhibitor effect in the treatment of gastroesophageal reflux disease and drug safety.Methods From October 2015 to February 2017 in Maoming people＇s Hospital outpatient gastroscopy in patients with gastroesophageal reflux disease in 90 cases,were randomly divided into 3 groups,each group 30,three groups of patients were given ray Bella with enteric coatedcapsules and Mosapride Citrate Capsules combined with Mosapride,Rabeprazole Sodium Enteric-coated Capsules capsule treatment,continuous treatment for 8 weeks.After the observation of the treatment effect and the treatment of the three groups of patients in drug adverse reaction.Results Effective treatment rate of combined treatment group（76.7%） and the total effective rate of treatment（90%） was significantly better than the Rebela tazobactam treatment group and Mosapride treatment group,the differences were statistically significant（P〈0.05）;drug adverse reactions of 3 groups were no significant differences in the incidence（P〉0.05）.Conclusion Mosapride combined with proton pump inhibitors in the treatment of gastroesophageal reflux disease,can significantly improve the clinical curative effect and high safety.